Ginkgo biloba for cognitive impairment and dementia

In people with cognitive complaints, we are unsure whether ginkgo improves global clinical status at six months, and it may be associated with an increased risk of AEs at three months. Ginkgo probably has no benefit at three months for cognition in multiple sclerosis; numeric data on AEs were unavailable, but studies did not suggest concerns. In people with MCI, ginkgo probably has little or no effect at six months on global status, cognition, or ADLS. There may be little or no difference in AEs, and there is little or no difference in SAEs, at up to 12 months. In people with dementia, there may be small to moderate benefits at six months for global status, cognition, and ADLs. There is probably little or no difference in AEs at up to 12 months, and there may be no difference in SAEs.

Authors

Institutions

Publication Details

Journal
Cochrane Database of Systematic Reviews
Published
2026-02-05
DOI
https://doi.org/10.1002/14651858.cd013661.pub2
Primary Topic
Ginkgo biloba and Cashew Applications
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ginkgo biloba for cognitive impairment and dementia

Emma Wolverson, Yuan Chi, Termeh Feinberg, Emilie Ludeman et al.
Cochrane Database of Systematic Reviews
Ginkgo biloba and Cashew Applications
article

Ginkgo biloba for cognitive impairment and dementia

Emma Wolverson, Yuan Chi, Termeh Feinberg, Emilie Ludeman, L. Susan Wieland, Kee-Hsin Chen, I-Hui Chen, Yanan Zhu, Hakima Amri
article en

Abstract

In people with cognitive complaints, we are unsure whether ginkgo improves global clinical status at six months, and it may be associated with an increased risk of AEs at three months. Ginkgo probably has no benefit at three months for cognition in multiple sclerosis; numeric data on AEs were unavailable, but studies did not suggest concerns. In people with MCI, ginkgo probably has little or no effect at six months on global status, cognition, or ADLS. There may be little or no difference in AEs, and there is little or no difference in SAEs, at up to 12 months. In people with dementia, there may be small to moderate benefits at six months for global status, cognition, and ADLs. There is probably little or no difference in AEs at up to 12 months, and there may be no difference in SAEs.

Cochrane Database of Systematic ReviewsVol. 2026(2)
Guangzhou University of Chinese Medicine (CN), University of Maryland, Baltimore (US), Georgetown University (US), Georgetown University Medical Center (US), Taipei Medical University Hospital (TW), Yale University (US), Guangzhou University (CN), University Memory and Aging Center (US), Yale New Haven Health System (US), Wan Fang Hospital (TW), Singapore Clinical Research Institute (SG), First Affiliated Hospital of Jinan University (CN), Taipei Medical University (TW), University of Baltimore (US), Guangzhou Medical University (CN), Kelly Services (United States) (US), McMaster University (CA)
Openalex Percentile: Top 64%
Ginkgo biloba and Cashew Applications
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Ginkgo biloba for cognitive impairment and dementia — Emma Wolverson, Yuan Chi, et al. · Cochrane Database of Systematic Reviews (2026) | TGRS Research Map | TGRS